{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:11:23Z","timestamp":1787019083903,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Fluoropyrimidine-based regimens are among the most commonly used chemotherapy combinations for the treatment of solid tumors. Several genetic polymorphisms that are implicated with fluoropyrimidine anabolism and catabolism have been associated with the development of life-threatening toxicities. Uridine triacetate is an FDA-approved antidote for 5-fluorouracil or capecitabine overdose and early-onset, life-threatening toxicity within 96\u2009h of last chemotherapy dose. To date, it is not accessible for Greek patients as per the current summary of product characteristic's time restrictions. We report and discuss the course and outcome of capecitabine toxicity in a 66-year-old female colorectal cancer patient with heterozygous dihydropyrimidine dehydrogenase deficiency. This paper highlights the difficulty in timely access of this lifesaving medication for Greek and possibly other European patients.<\/jats:p>","DOI":"10.1177\/1078155219865597","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T21:15:12Z","timestamp":1565039712000},"page":"747-753","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-8550","authenticated-orcid":false,"given":"Dimitra Ioanna","family":"Lampropoulou","sequence":"first","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Laschos","sequence":"additional","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lea","family":"Amylidi","sequence":"additional","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadni","family":"Angelaki","sequence":"additional","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Soupos","sequence":"additional","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Boumpoucheropoulos","sequence":"additional","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Papadopoulou","sequence":"additional","affiliation":[{"name":"GeneKor Medical SA, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Nanou","sequence":"additional","affiliation":[{"name":"Faculty of Nursing, Kapodistrian University of Athens, Athens, Greece"},{"name":"Intensive Care Unit, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Zidianakis","sequence":"additional","affiliation":[{"name":"Faculty of Nursing, Kapodistrian University of Athens, Athens, Greece"},{"name":"Intensive Care Unit, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nasioulas","sequence":"additional","affiliation":[{"name":"GeneKor Medical SA, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Fildissis","sequence":"additional","affiliation":[{"name":"Faculty of Nursing, Kapodistrian University of Athens, Athens, Greece"},{"name":"Intensive Care Unit, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[{"name":"Second Department of Medical Oncology, General Oncology Hospital of Kifissia \u201cAgioi Anargiroi\u201d, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"bibr1-1078155219865597","first-page":"2289","volume":"5","author":"Lamont E","year":"1999","journal-title":"Clin Cancer Res"},{"key":"bibr2-1078155219865597","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2031717"},{"key":"bibr3-1078155219865597","unstructured":"Nagai H and Sumino Y. Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Scientific Figure on ResearchGate, www.researchgate.net\/figure\/Fig-4-Anticancer-Mechanisms-of-5-fluorouracil-1-1-Inhibition-of-deoxyribonucleic_fig2_23458983 (2008, accessed 3 February 2019)."},{"key":"bibr4-1078155219865597","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00002"},{"key":"bibr5-1078155219865597","first-page":"2223","volume":"40","author":"Fraile RJ","year":"1980","journal-title":"Cancer Res"},{"key":"bibr6-1078155219865597","unstructured":"Lam YWF and Scott SA.\n                      Pharmacogenomics: challenges and opportunities in therapeutic implementation\n                      . 2nd ed. London: Elsevier Inc., 2019, p.19."},{"key":"bibr7-1078155219865597","unstructured":"Accord Healthcare Limited Fluorouracil (package insert). United Kingdom: Accord Healthcare Limited, 2017."},{"key":"bibr8-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1089\/dna.1995.14.1"},{"key":"bibr9-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1007\/s003840100358"},{"key":"bibr10-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04141.x"},{"key":"bibr11-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0169"},{"key":"bibr12-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0304"},{"key":"bibr13-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18425"},{"key":"bibr14-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.14.10.961"},{"key":"bibr15-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210374891"},{"key":"bibr16-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1159\/000078335"},{"key":"bibr17-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187313.83515.7e"},{"key":"bibr18-1078155219865597","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2012.0084"},{"key":"bibr19-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.11.1795"},{"key":"bibr20-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0638"},{"key":"bibr21-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr22-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1027684"},{"key":"bibr23-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30321"},{"key":"bibr24-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217732141"},{"key":"bibr25-1078155219865597","unstructured":"L Lo L, Lingaratnam S, Rowe C, et\u00a0al. An Australian experience of the use of uridine triacetate (Vistogard\u00ae) antidote for severe capecitabine toxicity \u2013 a case report, www.researchgate.net\/publication\/315697116_AN_AUSTRALIAN_EXPERIENCE_OF_THE_USE_OF_URIDINE_TRIACETATE_VISTOGARD_ANTIDOTE_FOR_SEVERE_CAPECITABINE_TOXICITY_-_A_CASE_REPORT (accessed 7 November 2016)."},{"key":"bibr26-1078155219865597","doi-asserted-by":"crossref","unstructured":"Oliver WD, Duffy AP, Hausner PF. Case report of capecitabine toxicity and use of uridine triacetate.\n                      J Oncol Pharm Pract\n                      2017; 25: 470\u2013473.","DOI":"10.1177\/1078155217730662"},{"key":"bibr27-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1841"},{"key":"bibr28-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X18786405"},{"key":"bibr29-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2017.05.021"},{"key":"bibr30-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"bibr31-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"bibr32-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.911"},{"key":"bibr33-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02869.x"},{"key":"bibr34-1078155219865597","first-page":"e783","volume":"8","author":"Saif MW","year":"2016","journal-title":"Cureus"},{"key":"bibr35-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1325"},{"key":"bibr36-1078155219865597","doi-asserted-by":"publisher","DOI":"10.1177\/1559325818803042"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219865597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219865597","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219865597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:38Z","timestamp":1777688498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219865597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1177\/1078155219865597"],"URL":"https:\/\/doi.org\/10.1177\/1078155219865597","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]}}}